NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal (STA)

Sofosbuvir-ledipasvir for treating genotype 1 chronic hepatitis C

Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
Manufacturers/sponsors Gilead Sciences (sofosbuvir- ledipasvir) Patient/carer groups Action on Hepatitis C Addiction Today (Addiction Recovery Foundation) Afiya Trust African Health Policy Network Alliance AVERT Black Health Agency British Liver Trust Compass UK Drugs Action Drugscope Equalities National Council GMFA - The Gay Men's Health Charity Haemophilia Alliance Haemophilis C Trust Liver4Life Muslim Council of Britain	General • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Commissioning Support Appraisals Service • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Commercial Medicines Unit • NHS Confederation • Scottish Medicines Consortium Possible comparator manufacturer(s) • Janssen (telaprevir) • Meda Pharmaceuticals (ribavirin) • Merck Sharp & Dohme (boceprevir, peginterferon alfa 2b, ribavirin) • Mylan UK (ribavirin)
 Muslim Health Network NAM Publications National AIDS Trust 	 Roche Products (peginterferon alfa 2a, ribavirin) Teva UK (ribavirin)
 Positively UK South Asian Health Foundation Specialised Healthcare Alliance Terrence Higgins Trust Transplant Support Network UK Harm Reduction Alliance YouthNet 	 <u>Relevant research groups</u> Centre for Sexual Health & HIV Research Cochrane Hepato-Biliary Group Foundation for Liver Research Health Research Authority MRC Clinical Trials Unit

National Institute for Health and Care Excellence

Provisional matrix for the proposed technology appraisal of sofosbuvir-ledipasvir for treating genotype 1 chronic hepatitis C

Consultees	Commentators (no right to submit or appeal)
 <u>Professional groups</u> Association for Clinical Biochemistry and Laboratory Medicine Association of Nurses in Substance Abuse British Association for Sexual Health and HIV British Association for the Study of the Liver British Association for the Study of the Liver Nurses Forum British Geriatrics Society British Infection Association British Liver Nurses Forum British Society of Gastroenterology British Viral Hepatitis Group Haemophilia Nurses Association HCV Action Hepatitis Nurse Specialist Forum Infection Control Nurses Association Medical Foundation for AIDS & Sexual Health NHS Blood and Transplant Royal College of Pathologists Royal College of Physicians Royal College of Physicians Royal Society of Medicine 	
 Society for General Microbiology United Kingdom Clinical Pharmacy Association United Kingdom Clinical Virology Network UK Haemophilia Centre Doctors' 	
 Organisation <u>Others</u> Department of Health NHS England NHS West Lancashire CCG NHS Windsor, Ascot and Maidenhead 	

National Institute for Health and Care Excellence Provisional matrix for the proposed technology appraisal of sofosbuvir-ledipasvir for treating genotype 1 chronic hepatitis C

Consultees	Commentators (no right to submit or appeal)
CCGWelsh Government	

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The manufacturer/sponsor of the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-manufacturer/sponsor consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the *British National Formulary*.

All non-manufacturers/sponsors commentators are invited to nominate clinical specialists or patient experts.

Evidence Review Group (ERG)

An independent academic group commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist the Appraisal Committee in reviewing the manufacturer/sponsor evidence submission to the Institute.

¹ Non manufacturer consultees are invited to submit statements relevant to the group they are representing.